IMWG Conference Series: ASCO & EHA 2023

Published 2023-06-16

Recommendations

07:58

Dr. Mikhael on Challenges, Advances in Multiple Myeloma Treatment
09:31

ASH 2023 | High-risk myeloma
09:52

ASH23: Post ASH Summary | Joseph Mikhael, MD
00:20

What is myeloma?
04:34

What Is the Future for CAR-T in Multiple Myeloma?
10:21

ASH23: Impact of Dexamethasone (Dex) Dose Strength on Newly Diagnosed Myeloma | Rahul Banerjee, MD
07:26

ASH23: Sonrotoclax in Combo with Dexamethasone for Relapsed Myeloma with t(11;14) | Dr. Hang Quach
12:56

ASH23: Perseus Trial: DARA + VRd vs. Vrd Alone in ASCT-Eligible Patients | Pieter Sonneveld, MD, PhD
1:27:09

IMWG Conference Series: ASH 2020
10:43

ASH23: Elranatamab Effective in Relapsed Myeloma Post-BCMA CAR-T | Daniel Sherbenou, MD, PhD
09:39

ASH23: Iceland’s iStopMM Study on Free Light Chains and MGUS | Thorir Einarsson Long, MD, PhD
58:05

MPE Webinar ASH 2023 myeloma and AL amyloidosis highlights
06:43

ASH23: STEM Trial Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy | Adam Cohen, MD
05:10

2023 Innovation and Impact Report | International Myeloma Foundation Reports on Key Wins in Myeloma
06:54

ASH23: CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma | Jens Hillengass, MD, PhD
57:07

CGC 2023 Webinar Series: Real world classification of variants in cancer
13:55

PFAS health effects and CDC guidelines on how to reduce PFAS exposure with Aaron Bernstein, MD, MPH
09:58

ASH23: KarMMa-3 Study: Ide-Cel for Triple-Class-Exposed RRMM Patients | Paula Rodriguez Otero, MD
09:44

ASH23: Relapsed Multiple Myeloma Treatment: GMMG Phase III ReLApsE Trial | Marc Andrea Baertsch, MD
$ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA$ 07:44

ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBA

Similar videos